Cardio-Oncology: Learning From the Old, Applying to the New

Frontiers in Cardiovascular Medicine

卷:7

Jun-ichi Abe¹  Syed Wamique Yusuf¹  Anita Deswal¹  Joerg Herrmann² 

[1] Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX, United States;

[2] Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States;

关键词: evidence-based medicine;    type 1 and type 2 cardiotoxicity;    anthracycline;    trastuzumab;    onco-cardiology;    cardio-oncology;   

DOI  :  10.3389/fcvm.2020.601893

来源: DOAJ

【 摘 要 】

The recent surge in cancer drug approval has provided us in cardio-oncology with a new and unique era, which modern medicine has not experienced before: the diminishing availability of “conventional” evidence-based medicine. The drastic and quick changes in oncology has made it difficult, and at times even impossible, to establish a meaningful evidence-based cardio-oncology practice by simply following the oncologists' practice. For the modern cardio-oncologist, it seems that a more proactive approach and methodology is needed. We believe that only through such an approach (learn from the old, and apply to the new) the cardio-oncologist will obtain meaningful evidence to perform their every-day practice in this new era.

【 授权许可】

Unknown